ProCE Banner Activity

Experts Answer Frequently Asked Questions on Hemophilia A Management

Clinical Thought
Read a discussion with 3 experts answering audience questions following 2 live Webcasts on contemporary management of hemophilia A.

Released: February 16, 2021

Expiration: February 15, 2022

Share

Faculty

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Rebecca Kruse-Jarres

Rebecca Kruse-Jarres, MD, MPH

Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme Corp

Takeda Pharmaceutical Co Ltd

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has disclosed that he has received consulting fees from Bayer, BioMarin, Global Blood Therapeutics, Grifols, Kedrion, Pfizer, Roche, Shire/Takeda, Spark, and UniQure; and serves on the speaker’s bureau for Bayer, Biomarin, Global Blood Therapeutics, NovoNordisk, Roche, and Shire/Takeda; and has ownership interest in Alnylam.

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received consulting fees from CSL Behring, Biomarin, Genentech/Roche, Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda and funds for research support paid to his institution from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure.

Rebecca Kruse-Jarres, MD, MPH

Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Rebecca Kruse-Jarres, MD, MPH, has disclosed that she has received consulting fees from Biomarin, CRISPR, CSL Behring, and Genentech/Roche; funds for research support from CSL Behring and Genentech/Roche; and fees for non-CME/CE services from Genentech/Roche; and that her spouse/partner has received consulting fees, funds for research support, and fees for non-CME/CE services from Genentech/Roche and fees for non-CME/CE services from Sanofi.